REV-MED secures global certifications for its autologous biologics kits
Exporting to over 30 countries and pursuing FDA approval to further expand market presence
[MHN Culture | Reporter Sunhye Park]
REV-MED (CEO Edward BG Shin) announced that it is accelerating its global market entry in the field of autologous stem cell-based therapies.
The company has received PMDA approval in Japan and NMPA certification in China for its TriCell PRP Kit and NovaStem—medical devices for extracting autologous biologics—and is currently undergoing clinical trials for FDA approval in the United States.
The global biologics market is projected to grow at an annual rate of over 10%, reaching approximately $615 billion USD by 2029.
Currently exporting to over 30 countries, REV-MED is steadily increasing its global market share. The company recently showcased its core products at MEDICA 2024 in Germany, one of the world's largest medical device exhibitions, signaling the full-scale launch of its global strategy.
To reinforce its scientific credibility, REV-MED has published more than 20 research studies, including SCI-indexed papers, and developed extraction kits capable of isolating regenerative cells from blood, bone marrow, and adipose tissue.
![REV-MED Logo Image]
Edward BG Shin, CEO of REV-MED, stated,
"Our success in global markets proves the excellence of Korean biotech."
"We aim to grow into a global leader in the biomedical industry through relentless innovation and R&D."
The company has designated 2025 as the foundation year for global market expansion, with plans to focus on FDA certification, expansion across Europe and Asia, and the development of next-generation technologies. REV-MED is committed to strengthening its competitiveness in the biomedical field through continuous research and development.
MHN Culture | Reporter Sunhye Park
Source: MHN Culture
Exporting to over 30 countries and pursuing FDA approval to further expand market presence
[MHN Culture | Reporter Sunhye Park]
REV-MED (CEO Edward BG Shin) announced that it is accelerating its global market entry in the field of autologous stem cell-based therapies.
The company has received PMDA approval in Japan and NMPA certification in China for its TriCell PRP Kit and NovaStem—medical devices for extracting autologous biologics—and is currently undergoing clinical trials for FDA approval in the United States.
The global biologics market is projected to grow at an annual rate of over 10%, reaching approximately $615 billion USD by 2029.
Currently exporting to over 30 countries, REV-MED is steadily increasing its global market share. The company recently showcased its core products at MEDICA 2024 in Germany, one of the world's largest medical device exhibitions, signaling the full-scale launch of its global strategy.
To reinforce its scientific credibility, REV-MED has published more than 20 research studies, including SCI-indexed papers, and developed extraction kits capable of isolating regenerative cells from blood, bone marrow, and adipose tissue.
![REV-MED Logo Image]
Edward BG Shin, CEO of REV-MED, stated,
"Our success in global markets proves the excellence of Korean biotech."
"We aim to grow into a global leader in the biomedical industry through relentless innovation and R&D."
The company has designated 2025 as the foundation year for global market expansion, with plans to focus on FDA certification, expansion across Europe and Asia, and the development of next-generation technologies. REV-MED is committed to strengthening its competitiveness in the biomedical field through continuous research and development.
MHN Culture | Reporter Sunhye Park
Source: MHN Culture